SEND Solutions - Standard for the Exchange of Nonclinical Data
Covance is leading the way in SEND solutions with a team of dedicated SEND experts. Learn more about SEND and Covance’s capabilities below.
Streamline your FDA submission process – avoid potential delays in development
View results in flexible formats – gain new perspectives, make better decisions
Test drive SEND today – be ready early, with help from Covance experts
Compliance with FDA requirements. A streamlined process.
Achieve compliant and secure FDA submissions. With new FDA requirements which took effect on December 17, 2016, you need to be able to receive and submit nonclinical study data in the SEND format for your toxicology studies. We can help you with any SEND requirements.
Fresh insights. Better decision making.
Imagine analyzing data from multiple studies, comparing data with historical controls, identifying trends and anomalies with ease, and then taking action. SEND makes it possible to share visual results with study stakeholders for improved communication.
Get SEND savvy early. Take a test drive.
You need to know that your SEND datasets are reliable and that your SEND process is going to work. Learn best practices from experts who know the SEND process. Reduce stress by getting ready early.
Experience that matters. Easy, secure implementation.
With Covance, you get a proven SEND partnership and process:
- Covance is part of the CDISC SEND Consortium and FDA/PhUSE Working Groups that are developing SEND standards and terminology
- Covance uses Pristima® software and Pinnacle 21 for high integrity. Open SEND.xpt data with SAS Viewer and easily save to spreadsheets. Receive files securely via FTP or Covance StudyTracker®
- Covance successfully delivers SEND today with more than 125 billion data points and greater than 500 studies performed
Covance is leading the way in SEND solutions with a team of dedicated SEND experts. Learn more about SEND and Covance’s capabilities:
“What is SEND?” (Presentation)
"SEND What to Expect" (Webinar)
Have Concerns about SEND? Join the SEND Discussion Thread
The FDA requires nonclinical data in all submissions for carcinogenicity and general toxicology studies initiated after December 17, 2016, to comply with data standards specifications. Learn more about the new SEND regulatory requirements: